MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
5.62
+0.13
+2.37%
After Hours: 5.67 +0.05 +0.89% 16:01 07/07 EDT
OPEN
5.48
PREV CLOSE
5.49
HIGH
5.76
LOW
5.37
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
5.76
52 WEEK LOW
1.435
MARKET CAP
784.91M
P/E (TTM)
-10.0286
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRS last week (0629-0703)?
Weekly Report · 1d ago
These low-priced stocks are flashing overbought signals
Seeking Alpha · 4d ago
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
NASDAQ · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/30 21:05
Weekly Report: what happened at ACRS last week (0622-0626)?
Weekly Report · 06/29 09:06
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Benzinga · 06/22 12:02
Weekly Report: what happened at ACRS last week (0615-0619)?
Weekly Report · 06/22 09:07
3 Penny Stocks Under $5 Backed by Real Revenue Growth
NASDAQ · 06/20 13:20
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.